Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
Key Takeaways
Bristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations.
The company raised its full-year adjusted EPS guidance and now projects adjusted revenue to land in the upper end of its previously issued range.
Revenue growth was driven by sales of its blood thinner Eliquis and cancer drug Opdivo.
Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.
The pharmaceutical giant now expects 2024 adjusted revenue to climb in the higher end of the low-single-digit percentage increase it called for in April. Adjusted earnings per share (EPS) guidance was raised to a range of $0.60 to $0.90, up from $0.40 to $0.70.
In the second quarter, Bristol-Myers Squibb posted adjusted EPS of $2.07 on revenue of $12.2 billion, beating consensus expectations of $1.63 and $11.54 billion of analysts polled by Visible Alpha.
Eliquis, Opdivo Sales Jump
Eliquis, Bristol-Myers Squibb’s blood thinner drug, was a major driver of growth for the company’s legacy portfolio. Worldwide revenue for the drug jumped 7% year-over-year to $3.42 billion, including more than $2.5 billion in the U.S.
The cancer drug Opdivo was a standout for what the company calls its growth portfolio, with revenue increasing 11% to nearly $2.4 billion.
Shares of Bristol-Myers Squibb jumped nearly 8% to $48.77 as of 10:30 a.m. Friday.
Read the original article on Investopedia.